



(11) **EP 1 517 883 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

Corrected version no 1 (W1 B1)

Bibliography INID code(s) 84

(51) Int Cl.:

C07C 235/34 (2006.01) **C07C 323/62** (2006.01)

A61K 31/19 (2006.01) **A61P 3/06** (2006.01)

A61P 3/10 (2006.01)

(48) Corrigendum issued on:

21.05.2008 Bulletin 2008/21

(86) International application number:

PCT/GB2003/002584

(45) Date of publication and mention
of the grant of the patent:

13.02.2008 Bulletin 2008/07

(87) International publication number:

WO 2004/000790 (31.12.2003 Gazette 2004/01)

(21) Application number: **03732713.7**

(22) Date of filing: **17.06.2003**

(54) **ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE**

ORTHO-SUBSTITUIERTE BENZOESÄUREDERIVATE ZUR BEHANDLUNG VON
INSULINRESISTENZ

DERIVES DE L'ACIDE BENZOIQUE ORTHO-SUBSTITUES DESTINES AU TRAITEMENT DE
L'INSULINORESISTANCE

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

AL LT LV MK

(73) Proprietor: **AstraZeneca AB**

151 85 Södertälje (SE)

(72) Inventor: **LI, Lanna**

S-431 83 Mölndal (SE)

(30) Priority: **20.06.2002 SE 0201935**

20.12.2002 SE 0203826

(56) References cited:

EP-A- 0 802 186

EP-A- 1 184 366

(43) Date of publication of application:

30.03.2005 Bulletin 2005/13

EP 1 517 883 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).